0etodo for treating premenstrual syndrome by administration of an inhibitor of angiotensin converting Enzyme.

• 1. 窦房结I_f当前抑制剂和血管紧张素转化酶抑制剂的组合在治疗心力衰竭中的用途 [P] . 中国专利： CN102284060A . 2011-12-21
• 2. 用于增加肌肉量的食品组合物、肌肉量增加剂、运动障碍综合征治疗剂、少肌症治疗剂、运动功能维持剂、肌萎缩相关基因表达抑制剂、肌肉蛋白质分解抑制剂、肌萎缩预防剂、肌肉合成相关基因表达促进剂及肌肉合成促进剂 [P] . 中国专利： CN111031812A . 2020-04-17
• 3. METHOD OF TREATING PREMENSTRUAL SYNDROME BY ADMINISTRATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR [P] . 世界知识产权组织专利： WO9302679A1 . 1993-02-18

  机译： 通过管理血管紧张素转化酶抑制剂治疗经前期综合征的方法

• 4. METHOD OF TREATING PREMENSTRUAL SYNDROME BY ADMINISTRATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR [P] . AU2413992A . 1993-03-02

  机译： 通过管理血管紧张素转化酶抑制剂治疗经前期综合征的方法

• 5. Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE are useful as inhibitors of Enkephalinase and angiotensin converting enzyme. [P] . 韩国专利： KR1019957000323A . 1995-01-16

  机译： 用作脑啡肽酶和ACE抑制剂的氨基乙酰基巯基乙酰酰胺衍生物可用作脑啡肽酶和血管紧张素转化酶的抑制剂。

• 1. Effects of angiotensin-converting enzyme inhibitor and angiotensin Ⅱ receptor blocker on one-year outcomes of patients with atrial fibrillation:insights from a multicenter registry study in China [J] . Si-Qi LYU, Yan-Min YANG, Jun ZHU, 老年心脏病学杂志（英文版） . 2020,第012期
• 2. Synthesis of the first highly potent inhibitor of the three vasopeptidases:endothelin converting enzyme (ECE),angiotensin converting enzyme (ACE) and neprilysin (NEP) [C] . Nicolas Inguimbert, Herve Poras, Pascale Coric, European Peptide Symposium . 2002
• 3. Extraction, Purification and Characterization of a Pure Peptide from Soybean to Demonstrate Anti-Proliferation Activity on Human Cancer Cells and Test the Ability of Soy Peptide Fractions in Reducing the Activity of Angiotensin-I Converting Enzyme. [D] . Rayaprolu, Srinivas. 2015
• 4. Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome [O] . Alberto Palazzuoli, Massimo Mancone, Gaetano M. De Ferrari, 2020
• 5. Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome [O] . Alberto Palazzuoli, Massimo Mancone, Gaetano M. De Ferrari, 2020
• 6. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Executive Summary. Comparative Effectiveness Review No. 18 [R] . 2009

• 1. Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients [J] . Neerja Aggarwal ,Pawan Kumar Kare ,Parul Varshney . 世界糖尿病杂志：英文版（电子版） . 2017,第3期
• 2. Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19 [J] . Xiao-Long Li ,Tao Li ,Qi-Cong Du . 世界临床病例杂志 . 2021,第020期
• 3. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension [J] . Ci Tian ,Nan Li ,Yi Bai . 世界临床病例杂志 . 2021,第001期
• 4. The Significance of Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use in Sudden Cardiac Death [J] . Makoto Onodera ,Satoshi Kikuchi ,Yasuhisa Fujino . 临床医学国际期刊（英文） . 2017,第8期
• 5. 血管紧张素转化酶抑制剂加复方丹参滴丸治疗糖尿病肾病的疗效观察 [C] . 肖文星 ,石如海 ,李文英 . 复方丹参滴丸美国FDA II期临床试验结果报告暨第四届学术研讨会 . 2010
• 6. Rho激酶的新型抑制剂WAR5腹腔给药治疗EAE的机制研究 [A] . 丁智斌 . 2015